# UK Microbiome Sequencing Services Market > UK Microbiome Sequencing Services Market Research Report By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) and By Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.7% - **2024:** $ 104.16 Million - **2025:** $ 122.6 Million - **2035:** $ 625.55 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) **Report ID:** MRFR/HC/52144-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-microbiome-sequencing-services-market-53906 --- ## Market Summary ## **UK Microbiome Sequencing Services Market Overview** As per MRFR analysis, the UK Microbiome Sequencing Services Market Size was estimated at 85.17 (USD Million) in 2023. The UK Microbiome Sequencing Services Market Industry is expected to grow from 93.6(USD Million) in 2024 to 487.32 (USD Million) by 2035. The UK Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 16.182% during the forecast period (2025 - 2035). ## **Key UK Microbiome Sequencing Services Market Trends Highlighted** The UK Microbiome Sequencing Services Market is undergoing substantial development as a result of the growing demand for personalized medicine and the advancement of genomic technologies. Healthcare professionals and researchers are increasing their exploration of microbiome analysis due to the growing recognition of the human microbiome's influence on health and disease. In the United Kingdom, public health initiatives are also emphasizing the importance of microbiome research in the comprehension of chronic diseases, resulting in a greater allocation of resources to related studies. Collaborations between universities and biotech firms in the United Kingdom present opportunities for development, as they promote innovation in microbiome applications in fields such as immune responses, metabolic disorders, and digestive health. In recent years, there has been a discernible trend of escalating investment in microbiome studies from private ventures and funding bodies. The UK government has been promoting research in this field through a variety of health agencies, acknowledging its potential for both economic benefits and health enhancement. Moreover, the incorporation of microbiome data into clinical practice is on the rise, as healthcare providers are attempting to customize treatments based on individual microbiome profiles by utilizing sequencing services. The trend toward regulatory support for microbiome-based interventions is also significant, which facilitates the introduction of novel products to the market.Furthermore, the expansion of databases that consolidate microbiome sequences improves the comparative knowledge that is accessible to researchers and clinicians, thereby enabling the production of more robust research outputs. In general, the UK Microbiome Sequencing Services Market is poised for further growth, as it is indicative of the nation's dedication to the improvement of health through the development of advanced microbiome research and applications. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **UK Microbiome Sequencing Services Market Drivers** Increasing Demand for Personalized Medicine The growing emphasis on personalized medicine is a significant driver of the UK Microbiome Sequencing Services Market. The UK government has been investing in initiatives like the NHS Genomic Medicine Service to enhance personalized treatments, aiming to incorporate genomic data to tailor healthcare services according to individual patient needs. Statistics show that personalized medicine can potentially make treatments 30% more effective, enhancing patient outcomes. As healthcare evolves, the microbe-based approaches will become integral in creating personalized healthcare plans, increasing the demand for microbiome sequencing services. Established organizations like Genomics England are leading these initiatives, and their focus on integrating sequencing technologies within clinical practices is likely to further spur growth in this market sector. Rising Awareness of Gut Health There has been a marked increase in public awareness regarding gut health and its connection to overall well-being, driving the requirement for microbiome sequencing. Recent surveys indicate that around 40% of the UK population is actively seeking information regarding probiotics and gut health. Public health campaigns supported by organizations such as the National Health Service (NHS) promote the significance of gut microbiomes in digestion and chronic disease prevention. With gut-related issues affecting nearly 1 in 10 individuals in the UK, the demand for microbiome sequencing services is forecasted to escalate. This trend is further supported by Research and Development activities in the field, as companies focus on leveraging sequencing to better understand gut-health links. Growth in Nutrition and Wellness Market The increasing focus on nutrition and wellness is pushing the demand for microbiome sequencing services in the UK Microbiome Sequencing Services Market Industry. The UK nutritional supplements market has experienced significant growth, with emerging reports indicating a potential valuation increase of 25% over the next few years. Companies like ProbioFerm are actively pursuing microbiome sequencing to innovate and develop products that cater to these new wellness trends. The emphasis on health-conscious living among consumers, coupled with the evolving understanding of how gut health impacts wellness, supports a strong growth trajectory for microbiome sequencing services in the UK market. Advancements in Sequencing Technologies Technological advancements in sequencing methods are another powerful driver for the UK Microbiome Sequencing Services Market. Organizations such as the Wellcome Sanger Institute are continuously innovating in sequencing technology, leading to lower costs and higher accuracy in microbiome analysis. Recent breakthroughs in next-generation sequencing have made microbiome analysis more accessible to clinical labs, lowering the cost by up to 40% in just a few years. As sequencing technology becomes more efficient, researchers and healthcare professionals are expected to incorporate microbiome data into a broader range of applications, therefore underscoring the potential for market growth in the UK. ## **UK Microbiome Sequencing Services Market Segment Insights** ### **Microbiome Sequencing Services Market Technology Insights** The UK Microbiome Sequencing Services Market, specifically within the Technology segment, is witnessing notable advancements driven by increasing interest in genomics and personalized medicine. This segment encompasses various approaches, such as Sequencing by Litigation (SBL), which is gaining traction due to its precision in resolving complex genetic information, thus contributing to advancements in microbial research and clinical diagnostics. Sequencing by Synthesis (SBS) showcases its robustness and cost-effectiveness, making it a preferred choice for many researchers pursuing large-scale sequencing initiatives. With the rise of synthetic biology, Short Gun Sequencing has emerged as a powerful method to identify and characterize a wide array of microbial communities, essential for understanding their functions in health and disease.Targeted Gene Sequencing stands out as a vital technique that allows for the focused analysis of specific genes, making it particularly useful in clinical applications, where it aids in identifying disease-associated variants within microbial genomes. RNA Sequencing, known for its capacity to provide insight into gene expression and microbial interactions, plays an integral role in comprehending microbiome dynamics. Each of these methodologies contributes significantly to the overall efficiency and accuracy of microbiome research, addressing the growing demands for more nuanced population and environmental health studies across the UK. The diversity of sequencing technologies not only ensures comprehensive analysis capabilities but also opens up a plethora of opportunities for innovation, enhancing our understanding of the complex relationships within microbial ecosystems. Overall, the UK Microbiome Sequencing Services Market industry is positioned for robust growth, fueled by technological advancements and increased investment in health and biotechnology research, paving the way for novel applications in drug discovery, diagnostics, and therapeutic strategies. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **Microbiome Sequencing Services Market Application Insights** The UK Microbiome Sequencing Services Market, particularly within the Application segment, showcases diverse areas of focus, reflecting varying healthcare needs. Gastrointestinal Diseases have become increasingly significant due to the rising prevalence of disorders like irritable bowel syndrome and inflammatory bowel disease, driving demand for microbiome analysis. Infectious Diseases follow closely, with the growing threat of antibiotic-resistant pathogens making microbiome sequencing critical for understanding microbial behaviors and treatment efficacy. In the realm of Central Nervous System (CNS) Diseases, research linking gut health to neurological conditions emphasizes the relevance of microbiome studies in developing new therapeutic options. Oncology also stands out, as understanding tumor microbiomes offers potential pathways for innovative cancer treatments. Additionally, the 'Others' category includes applications in metabolic and autoimmune disorders, providing a comprehensive overview of the sector's expansion. Market growth in these areas is propelled by advancements in sequencing technology, increasing investment in Research and Development, and heightened awareness of microbiome roles in health, positioning the UK as a leader in microbiome research and application. **UK Microbiome Sequencing Services Market Key Players and Competitive Insights:** The UK Microbiome Sequencing Services Market is rapidly evolving, showcasing a competitive landscape driven by advancements in genomic technologies and growing awareness of the microbiome's role in human health. As research into the human microbiome expands, the demand for sequencing services has significantly increased, leading to an influx of players seeking to capitalize on this burgeoning sector. Companies in this market are focusing on innovation, expanding their service offerings, and enhancing operational efficiencies to meet the diverse needs of researchers and healthcare practitioners. This competitive landscape is characterized by a mix of established firms and new entrants, all vying for market share in various segments, including academic research, clinical applications, and personalized medicine.uBiome has established a substantial presence in the UK Microbiome Sequencing Services Market, recognized for its pioneering efforts in microbiome research and consumer testing. The company's strength lies in its innovative approach to providing comprehensive sequencing solutions tailored to the needs of both academic institutions and private sector clients. By leveraging advanced sequencing technologies and robust bioinformatics capabilities, uBiome delivers high-quality insights into microbiome composition and functionality. Their focus on supporting scientific research with user-friendly platforms has enabled them to build strong partnerships within the UK’s research community, further solidifying their reputation as a leader in the microbiome field.Zymo Research is another key player in the UK Microbiome Sequencing Services Market, renowned for its commitment to precision and innovation in biological research. The company’s broad portfolio includes essential products and services such as DNA/RNA extraction kits, library preparation solutions, and next-generation sequencing (NGS) services specifically tailored for microbiome analysis. Zymo Research boasts a strong market presence backed by its rigorous quality control standards and comprehensive support for clients. The company has strategically engaged in mergers and collaborations that enhance its capabilities and offerings within the UK market, positioning itself as a trusted provider in microbiome sequencing. Through its continuous investment in research and development, Zymo Research strives to advance the understanding of the microbiome and drive innovation in applications related to health and disease. **Key Companies in the UK Microbiome Sequencing Services Market Include:** - uBiome - Zymo Research - Macrogen - Ebiogen - [Qiagen](https://www.qiagen.com/us/applications/genomic-services/microbiome-profiling-services) - Ginkgo Bioworks - Thermo Fisher Scientific - Illumina - Metabiota - BGI Group - Oxford Nanopore Technologies - Novogene - Genomatix - Aspect Biosystems - Enterome **UK Microbiome Sequencing Services Market Industry Developments** Recent developments in the UK Microbiome Sequencing Services Market indicate a growing interest in advanced microbial analysis technologies. Companies such as Illumina and Qiagen continue to lead innovations, focusing on integration with healthcare systems as personalized medicine gains traction. Ginkgo Bioworks has been working on scaling its biotechnology capabilities, while Thermo Fisher Scientific has launched new services that enhance sequencing efficiency. In terms of market activity, in August 2023, Novogene announced a strategic partnership with prominent UK-based institutions to enhance genomic sequencing capabilities, emphasizing the collaborative effort in advancing microbiome research. Additionally, Enterome secured funding for its microbiome-related projects in July 2023, reflecting the increasing investments in this space. The market has seen significant valuation growth, driven primarily by demand for microbiome analysis in clinical applications and research development. In the past few years, the UK has witnessed heightened regulatory support for microbiome research, underlining its commitment to being a leader in microbial genomics education and innovation, which in turn is stimulating growth and competitive dynamics among key players in the market. ## **UK Microbiome Sequencing Services Market Segmentation Insights** ### **Microbiome Sequencing Services Market Technology****Outlook** - Sequencing by Litigation (SBL) - Sequencing by Synthesis (SBS) - Short Gun Sequencing - Targeted Gene Sequencing - RNA Sequencing - Others ### **Microbiome Sequencing Services Market Application****Outlook** - Gastrointestinal Diseases - Infectious Diseases - CNS Diseases - Oncology - Others ## Market Drivers ### Supportive Regulatory Environment A supportive regulatory environment in the UK is fostering growth in the microbiome sequencing-services market. Regulatory bodies are increasingly recognizing the importance of microbiome research and are establishing guidelines that facilitate innovation and ensure safety. This environment encourages investment in microbiome-related research and development, which is crucial for the advancement of sequencing technologies. The UK government has allocated £50 million to support microbiome research initiatives, indicating a commitment to enhancing the sector. Such support is likely to stimulate market growth as companies seek to comply with regulations while developing new services. ### Increasing Awareness of Gut Health The rising awareness of gut health among the UK population is a pivotal driver for the microbiome sequencing-services market. As individuals become more informed about the connection between gut microbiota and overall health, there is a growing demand for services that can provide insights into personal microbiomes. This trend is reflected in the increasing number of consumers seeking microbiome testing to understand their digestive health, which is projected to grow at a CAGR of 15% over the next five years. The microbiome sequencing services market is positioned to benefit from this heightened interest. Consumers are looking for tailored solutions to improve their health outcomes. ### Rising Investment in Biotechnology The microbiome sequencing services market is experiencing a surge in investment from both public and private sectors. This investment is a key driver of its growth. The UK biotechnology sector has seen increased funding, with venture capital investments reaching £1.5 billion in 2025. This influx of capital is enabling companies to innovate and expand their service offerings in microbiome sequencing. As more startups and established firms enter the market, competition is expected to intensify, leading to advancements in technology and service delivery. This trend suggests a robust future for the microbiome sequencing-services market as it attracts further investment. ### Expansion of Healthcare Applications The expansion of healthcare applications utilizing microbiome sequencing is significantly influencing the microbiome sequencing-services market. With advancements in understanding the role of microbiomes in various diseases, including obesity, diabetes, and autoimmune disorders, healthcare providers are increasingly integrating microbiome analysis into patient care. This integration is expected to enhance diagnostic accuracy and treatment efficacy, potentially increasing the market size by £200 million by 2027. As healthcare professionals recognize the value of microbiome data, the demand for sequencing services is likely to surge, driving growth in the market. ### Growing Consumer Interest in Preventive Healthcare The growing consumer interest in preventive healthcare is significantly impacting the microbiome sequencing-services market. As individuals become more proactive about their health, there is an increasing demand for services that provide insights into personal health risks and preventive measures. The market is projected to grow by 20% annually as consumers seek microbiome analysis to inform lifestyle choices and dietary adjustments. This shift towards preventive healthcare is likely to drive the adoption of microbiome sequencing services, as consumers look for ways to enhance their well-being and prevent potential health issues. ## Future Outlook The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) is projected to grow at a 17.7% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing health awareness, and technological innovations. **New opportunities:** - Development of subscription-based microbiome analysis services - Partnerships with healthcare providers for integrated health solutions - Expansion into agricultural microbiome applications for crop enhancement By 2035, the market is expected to be robust, driven by diverse applications and innovative service offerings. ## Segment Insights ### By Technology: Sequencing by Litigation (Largest) vs. RNA Sequencing (Fastest-Growing) In the UK microbiome sequencing-services market, Sequencing by Litigation (SBL) currently holds the largest market share, reflecting its deep integration into various research and clinical applications. This segment benefits from a robust demand for precision and accuracy in genetic analysis, particularly in legal contexts where genomic evidence is critical. Meanwhile, RNA Sequencing is emerging as a strong contender, rapidly gaining traction due to its innovative applications in transcriptomics and personalized medicine, appealing to a growing base of researchers and healthcare providers. The growth trends in these technologies are primarily driven by advancements in sequencing technologies, decreasing costs, and increased public and private investment in genomics. SBL continues to thrive as its applications expand, while RNA Sequencing is often highlighted for its potential in unveiling gene expression patterns and its adaptability in various fields, including cancer research and therapy development. Overall, the interplay of these technologies reflects a dynamic landscape where traditional methods and cutting-edge innovations coexist and evolve. Technology: SBL (Dominant) vs. RNA Sequencing (Emerging) Sequencing by Litigation (SBL) dominates the current landscape due to its extensive application in forensic genomics, making it highly sought after by institutions requiring precise legal documentation of genetic evidence. This method's reliability and legal standing keep it firmly planted at the forefront, fostering solid market stability. On the other hand, RNA Sequencing, labeled as an emerging technology, is rapidly evolving to become vital in the exploration of gene expression and biomarker discovery. Its flexibility and heightened capability to provide insights into various biological processes make it attractive to researchers in clinical settings and beyond. While SBL remains the dominant force within the market, the burgeoning demand for RNA Sequencing positions it as a key player for future advancements. ### By Application: Gastrointestinal Diseases (Largest) vs. Oncology (Fastest-Growing) In the UK microbiome sequencing-services market, the distribution of market share among key application segments reveals that Gastrointestinal Diseases holds the largest portion, driven by the rising prevalence of gut-related disorders among the population. Infectious Diseases and CNS Diseases follow, each contributing significantly but at smaller rates. Oncology is emerging as a crucial segment, driven by increased research and applications of microbiome data in cancer therapies. Growth trends in the application segment indicate an increasing focus on personalized medicine and targeted treatments, particularly within Oncology. The demand for advanced sequencing technologies and their applications in understanding complex diseases drives innovation and market expansion. As healthcare providers recognize the benefits of microbiome insights, investments in research for all listed segments are expected to grow, fostering a competitive landscape in the market. Gastrointestinal Diseases (Dominant) vs. Oncology (Emerging) Gastrointestinal Diseases represents the dominant application segment in the UK microbiome sequencing-services market, primarily due to the high incidence of diseases such as Irritable Bowel Syndrome (IBS) and inflammatory bowel diseases, where microbiome analysis provides critical insights. The segment's established position benefits from a solid foundation of clinical usage and research. Conversely, Oncology is labeled as an emerging segment poised for rapid growth, driven by advancements in understanding the microbiome's role in cancer development and treatment responses. As healthcare evolves, the integration of microbiome data into oncology not only enhances patient profiling but also aids in the customization of treatment strategies, reflecting the significant untapped potential in this area. ## Competitive Benchmarking The microbiome sequencing-services market is currently characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Qiagen (DE) are at the forefront, leveraging their extensive research capabilities and innovative product offerings. Illumina (US) focuses on enhancing its sequencing platforms, while Thermo Fisher Scientific (US) emphasizes integration of its technologies into clinical workflows. Qiagen (DE) is strategically positioning itself through partnerships aimed at expanding its diagnostic capabilities. Collectively, these strategies foster a competitive environment that is increasingly centered on technological innovation and strategic collaborations.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements that smaller firms often follow. In October Illumina (US) announced a partnership with a leading healthcare provider to integrate its sequencing technology into routine clinical diagnostics. This strategic move is likely to enhance patient outcomes by enabling more precise and personalized treatment options, thereby solidifying Illumina's position as a leader in the market. The collaboration underscores the growing trend of integrating advanced sequencing technologies into healthcare systems, which may reshape patient care paradigms. In September Thermo Fisher Scientific (US) launched a new suite of microbiome analysis tools designed to streamline research workflows. This initiative not only reflects the company's commitment to innovation but also addresses the increasing demand for efficient and comprehensive microbiome analysis solutions. By enhancing its product offerings, Thermo Fisher Scientific (US) is likely to attract a broader customer base, further entrenching its competitive stance in the market. In August Qiagen (DE) expanded its portfolio by acquiring a microbiome-focused startup, which specializes in novel sequencing technologies. This acquisition is indicative of Qiagen's strategy to bolster its capabilities in the microbiome space, potentially allowing it to offer more comprehensive solutions to its clients. Such strategic acquisitions may enable Qiagen to leverage new technologies and expertise, thereby enhancing its competitive edge. As of November the competitive trends in the microbiome sequencing-services market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. This shift suggests a future where innovation and quality will be paramount in determining market leadership. ## Recent News & Developments Recent developments in the UK Microbiome Sequencing Services Market indicate a growing interest in advanced microbial analysis technologies. Companies such as Illumina and Qiagen continue to lead innovations, focusing on integration with healthcare systems as personalized medicine gains traction. Ginkgo Bioworks has been working on scaling its biotechnology capabilities, while Thermo Fisher Scientific has launched new services that enhance sequencing efficiency. In terms of market activity, in August 2023, Novogene announced a strategic partnership with prominent UK-based institutions to enhance genomic sequencing capabilities, emphasizing the collaborative effort in advancing microbiome research. Additionally, Enterome secured funding for its microbiome-related projects in July 2023, reflecting the increasing investments in this space. The market has seen significant valuation growth, driven primarily by demand for microbiome analysis in clinical applications and research development. In the past few years, the UK has witnessed heightened regulatory support for microbiome research, underlining its commitment to being a leader in microbial genomics education and innovation, which in turn is stimulating growth and competitive dynamics among key players in the market. ## Report Scope | MARKET SIZE 2024 | 104.16(USD Million) | | --- | --- | | MARKET SIZE 2025 | 122.6(USD Million) | | MARKET SIZE 2035 | 625.55(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.7% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) | | Segments Covered | Technology, Application | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in microbiome sequencing-services market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation in microbiome sequencing services within the UK market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK microbiome sequencing-services market?** A: The market valuation was $104.16 Million in 2024. **Q: What is the projected market size for the UK microbiome sequencing-services market by 2035?** A: The market is projected to reach $625.55 Million by 2035. **Q: What is the expected CAGR for the UK microbiome sequencing-services market during the forecast period?** A: The expected CAGR is 17.7% from 2025 to 2035. **Q: Which technology segments are included in the UK microbiome sequencing-services market?** A: Key technology segments include Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and Others. **Q: What was the market value for Sequencing by Synthesis (SBS) in 2024?** A: The market value for Sequencing by Synthesis (SBS) was $20.83 Million in 2024. **Q: Which applications are driving growth in the UK microbiome sequencing-services market?** A: Growth is driven by applications in Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, and Others. **Q: What was the market value for Gastrointestinal Diseases in 2024?** A: The market value for Gastrointestinal Diseases was $30.0 Million in 2024. **Q: Who are the key players in the UK microbiome sequencing-services market?** A: Key players include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, Genomatix, Microbiome Insights, Second Genome, and CosmosID. **Q: What is the projected market value for RNA Sequencing by 2035?** A: The projected market value for RNA Sequencing is expected to reach $50.0 Million by 2035. **Q: What was the market value for Oncology applications in 2024?** A: The market value for Oncology applications was $15.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-microbiome-sequencing-services-market-53906*